Northland Capital Markets Remains Bullish on Wright Medical Group (WMGI) Following AUGMENT FDA Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pre-Open Stock Movers 09/02: (SURG) (VRA) (WMGI) Higher; (RJET) (DGLY) (HTWR) Lower (more...)
September 2, 2015 9:23 AM EDTA listing of stocks moving in the pre market trading session:
Synergetics USA, Inc. (NASDAQ: SURG) 53% HIGHER; Synergetics USA and Valeant Pharmaceuticals International ("Valeant"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), announced that they have entered into a definitive agreement under which Valeant will acquire Synergetics for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments... More
Augment Approval Provides Catalyst for Wright Medical (WMGI), Brean Capital Says
September 2, 2015 7:26 AM EDTBrean Capital analyst Jason Wittes reiterated a Buy rating and $38 price target on Wright Medical (NASDAQ: WMGI), saying Augment approval should be a catalyst.
Wittes commented, "After the market close yesterday (September 1, 2015), WMGI reported that its BioMimetic subsidiary had finally received an approval order from... More
Wright Medical (WMGI) Augment Approval Removes Overhang, Leerink Partners Says
September 2, 2015 6:24 AM EDTLeerink Partners analyst Richard Newitter reiterated an Outperform rating and $31 price target on Wright Medical (NASDAQ: WMGI), saying Augment approval unlocks a key growth catalyst and removes an overhang.
Newitter commented, "We expect WMGI shares to react positively following FDA... More
Wright Medical Group's (WMGI) AUGMENT Bone Graf PMA Receives FDA Approal
September 1, 2015 4:14 PM EDTWright Medical Group (NASDAQ: WMGI) announced that its BioMimetic subsidiary has received an approval order from the U.S. Food and Drug Administration (FDA) for its Premarket Approval Application (PMA) for AUGMENT Bone Graft. The approval order indicates that FDA determined that AUGMENT® Bone Graft is safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications. Wright can now initiate commercial sale and distribution of AUGMENT® Bone Graft in the U.S.
Robert Palmisano, president and chief executive officer, stated, The FDA approval of AUGMENT marks a capstone... More
Wright Medical Group (WMGI) Reports FDA Approval of AUGMENT Bone Graft
September 1, 2015 4:13 PM EDTWright Medical Group, Inc. (NASDAQ: WMGI) today announced that its BioMimetic subsidiary has received an approval order from the U.S. Food and Drug Administration (FDA) for its Premarket Approval Application (PMA) for AUGMENT® Bone Graft. The approval order indicates that FDA determined that AUGMENT® Bone Graft is safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications. Wright can now initiate commercial sale and distribution of AUGMENT® Bone Graft in the U.S.
Robert Palmisano, president and chief executive officer, stated, The FDA approval of AUGMENT marks a capstone... More
